The study, published in BMC Pediatrics, applied formal survival analysis to the cohort, using the log-rank test to compare survival across patient groups and the Cox proportional hazards regression model to isolate independent predictors of mortality. This statistical framework, widely regarded as the workhorse of epidemiological survival research, allows investigators to estimate a hazard ratio for each candidate risk factor: a value above one signals an elevated instantaneous risk of death at any point in follow-up, while a confidence interval that excludes one indicates a finding unlikely to be due to chance alone. The approach matters because congenital heart disease outcomes are shaped by many overlapping variables, from nutrition to geography, and only multivariable modeling can begin to disentangle them.

The headline finding concerns where children live. Those residing in rural areas faced a significantly higher hazard of death than their urban counterparts, with a hazard ratio of 1.33 and a 95 percent confidence interval of 1.06 to 1.66, corresponding to a p-value of 0.013. In practical terms, a rural child with a congenital heart defect carried roughly a one-third higher risk of dying at any given moment during follow-up compared with an otherwise similar urban child. The authors attribute this gap to the geography of specialized care in Uganda: the Uganda Heart Institute, the country’s principal referral center for pediatric cardiac disease, sits in Kampala, and families in remote districts face long, costly journeys to reach echocardiography, cardiac surgery, and follow-up clinics.

Nutrition emerged as an even more powerful predictor. Underweight children, defined against standard body mass index reference ranges, had more than twice the hazard of death compared with children of normal weight, with a hazard ratio of 2.07, a 95 percent confidence interval of 1.60 to 2.69, and a p-value below 0.001. The physiological logic behind this association is well established in pediatric cardiology. Children with significant heart defects burn extra calories simply to keep their overworked circulation going, while simultaneously struggling to feed because breathlessness and fatigue make sucking and swallowing difficult. The result is a vicious cycle in which malnutrition weakens immune defenses, impairs surgical candidacy, and accelerates heart failure, and in which the underlying cardiac defect in turn deepens the nutritional deficit.

Defect severity also shaped survival, though the pattern contained a statistical wrinkle that the researchers themselves flagged. Compared with children classified as having critical defects, those with moderate defects showed a higher hazard of death, with a hazard ratio of 1.98, a 95 percent confidence interval of 1.25 to 3.13, and a p-value of 0.004. At first glance this seems paradoxical, since critical defects are by definition the most severe. The authors caution that this finding should be interpreted carefully. One plausible explanation is a form of survival bias: infants with the most critical lesions may die before ever reaching the registry, or may be prioritized for urgent intervention, while children with moderate defects linger longer without definitive treatment, accumulating risk over time. Non-critical defects, by contrast, were not significantly associated with mortality in the model.

Perhaps the most actionable finding involved timing. The age or stage at which a child’s defect was diagnosed was significantly associated with mortality, with a hazard ratio of 1.67, a 95 percent confidence interval of 1.30 to 2.14, and a p-value below 0.001. Later diagnosis carried a higher hazard of death. This is the clearest signal in the dataset that the system itself, rather than biology alone, is costing lives. Congenital heart defects are frequently detectable in infancy through pulse oximetry screening, prenatal ultrasound, and attentive newborn examination, yet in much of sub-Saharan Africa the diagnosis arrives only after months of unexplained poor feeding, recurrent pneumonia, or frank heart failure, when secondary damage to the lungs and heart muscle is already established.

Not every candidate factor survived statistical scrutiny. Oxygen level, a variable that clinicians might intuitively expect to matter, was not significantly associated with survival in this cohort. The authors do not overinterpret this null result, but it serves as a reminder that in resource-limited settings the dominant determinants of outcome may be structural and logistical, such as where a family lives, how well a child is nourished, and how quickly the diagnosis is made, rather than the physiological parameters that dominate decision-making in well-resourced intensive care units.

The study’s methods deserve attention for what they reveal about the state of pediatric cardiac epidemiology in the region. By mining electronic patient records from a five-year window, the team avoided the cost and delay of prospective recruitment, and the retrospective design was approved by the Ethics Committee of the School of Statistics and Planning at Makerere University, with permission from the Uganda Heart Institute Research Committee. Because the analysis used existing data, the requirement for additional informed consent was waived in accordance with national guidelines, and the original data collection had already secured consent from participants or their legal guardians. The researchers report no specific funding for the work and declare no competing interests.

The global context sharpens the urgency of these numbers. In high-income countries, most congenital heart defects are diagnosed prenatally or within the first weeks of life, and the majority of affected children now survive to adulthood thanks to staged surgical repair, catheter-based interventions, and lifelong specialized follow-up. In Uganda and much of the continent, the pipeline looks radically different: few centers perform pediatric cardiac surgery, waiting lists stretch for years, and many families never reach the operating table at all. The result is a survival gap that is not primarily a mystery of biology but a measurable consequence of health system capacity, and the new hazard ratios quantify that consequence with unusual precision for the region.

The authors’ conclusions point to concrete interventions. Strengthening early screening programs, particularly newborn pulse oximetry and structured infant examinations, could shift diagnoses to earlier, more treatable stages. Improving nutritional support for children with known cardiac lesions could attack the malnutrition-mortality cycle directly, and expanding outreach and referral pathways for rural families could erode the geographic penalty captured in the 1.33 hazard ratio. None of these measures requires a breakthrough in cardiac surgery; they require screening tools, feeding support, and transport systems that already exist and simply need to reach the children who need them. As congenital heart defects continue to contribute substantially to childhood deaths across sub-Saharan Africa, this Ugandan cohort study provides both a warning and a roadmap: the children most likely to die are those who live far from care, arrive undernourished, and are found too late, and each of those risks is, in principle, fixable.

Subject of Research: Survival and mortality risk factors among children with congenital heart defects in Uganda

Article Title: Survival and factors associated with mortality among children with congenital heart defects at the Uganda Heart Institute, Mulago National Referral Hospital

Article References: Lovisa, N., Atuhaire, L., Asiimwe, J. B., & Nsimbe, D. (2026). Survival and factors associated with mortality among children with congenital heart defects at the Uganda Heart Institute, Mulago National Referral Hospital. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07782-7

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07782-7

Keywords: congenital heart defects, pediatric mortality, survival analysis, Cox proportional hazards model, Uganda Heart Institute, sub-Saharan Africa, malnutrition, rural health access, early diagnosis, BMC Pediatrics, Survival, factors

The condition in question is 19p13.3 microdeletion syndrome, a rare and clinically heterogeneous genomic disorder caused by the loss of a small stretch of genetic material near the tip of the short arm of chromosome 19. Because the deleted segment can vary considerably in size from one patient to another, the syndrome does not present as a single recognizable disease. Instead, affected individuals may show global developmental delay, a range of congenital anomalies, and distinct craniofacial differences, with the precise combination and severity of symptoms depending heavily on which genes fall within the deleted region. This genotype-phenotype relationship is a central theme in the literature on the disorder and is precisely what makes each new case report valuable to clinicians trying to map the syndrome’s boundaries.

In the newly reported case, the infant was referred for evaluation of multisystemic complications that had already produced a daunting list of problems. Clinical examination revealed congenital heart defects and severe cardiomegaly, an abnormal enlargement of the heart that in this instance proved fatal. The child also presented with limb anomalies, macrocephaly, or an unusually large head, and recurrent pulmonary infections that compounded the clinical picture. Gastrointestinal manifestations, including vomiting and diarrhea, were a prominent feature of the illness. The authors note that digestive symptoms have rarely been reported in association with this condition, making their patient’s presentation particularly noteworthy for the expanding clinical record.

The diagnostic breakthrough came through a technique known as oligo-array comparative genomic hybridization, or oligo-array CGH. This laboratory method works by comparing a patient’s DNA against a reference genome on a microarray chip populated with thousands of short oligonucleotide probes covering the genome. Differences in fluorescence signal reveal regions where the patient has either lost or gained genetic material, often at a resolution far finer than a standard karyotype can achieve. In this case, the analysis uncovered a deletion measuring 1.8 megabases, a stretch of DNA encompassing 55 genes. Identifying the exact size and gene content of such a deletion is essential, because it allows clinicians to compare the patient against previously reported cases and to begin assigning specific features to specific genes.

Among the 55 genes within the deleted interval, several have already attracted attention in earlier studies of 19p13.3 deletions. The MAP2K2 gene, which encodes the kinase MEK2, a component of the RAS-MAPK signaling pathway that governs cell proliferation and differentiation, has been implicated in cases resembling cardiofaciocutaneous syndrome, a RASopathy characterized by heart defects, distinctive facial features, skin abnormalities, and developmental delay. Previous work has also suggested that PIAS4, a gene involved in sumoylation and the regulation of protein function, may be a major contributor to the proximal 19p13.3 microdeletion phenotype. Other genes in the region have been linked to cardiac development, including members of the ZBTB family of transcription factors, and to brain growth, such as the lamin genes whose variants cause primary microcephaly and the cell-cycle regulator CDH1, whose disruption has been associated with microcephaly, psychomotor retardation, and epilepsy.

The gastrointestinal findings in this case deserve particular emphasis. Although congenital heart disease and neurodevelopmental problems dominate the published literature on 19p13.3 microdeletions, digestive complications have appeared only sporadically. One earlier report described a newborn with a 19p13.3 deletion including MAP2K2 who had cardio-facio-cutaneous syndrome together with gastrointestinal defects, and another described a child with a chromosome 19p13.3 deletion in the context of Peutz-Jeghers syndrome and congenital heart defect. The vomiting and diarrhea observed in the Iranian infant, occurring alongside severe cardiac disease, suggest that the digestive system may be more frequently involved in this syndrome than the sparse literature indicates, and that the gene content of larger deletions may include factors necessary for normal gastrointestinal development or function.

The fatal outcome of the case also highlights the severity that 19p13.3 microdeletions can reach when the deleted segment is large. Severe cardiomegaly in an infant is a grave finding, often reflecting structural heart defects, myocardial dysfunction, or volume overload, and in combination with recurrent pulmonary infections it can create a lethal cycle in which cardiac compromise worsens respiratory disease and vice versa. The authors describe their patient’s phenotype as complex and multisystemic, and the report’s title explicitly characterizes the case as fatal. For clinicians, the message is that infants presenting with combinations of congenital heart defects, unusual head size, limb anomalies, and unexplained gastrointestinal symptoms may warrant genomic investigation even when the initial suspicion does not point to a chromosomal disorder.

The technique used to reach the diagnosis also carries a broader lesson for pediatric medicine. Oligo-array CGH has become a cornerstone of modern cytogenetics precisely because it can detect copy-number variants, deletions, and duplications that are invisible under the microscope. In rare syndromes such as this one, where the phenotype overlaps with many other conditions, genomic analysis is often the only route to a definitive answer. The authors of the report argue that their case underscores the importance of such analysis in understanding the underlying disease mechanisms of the syndrome. Each precisely characterized deletion narrows the search for the genes responsible for individual features, a process already illustrated in the literature by a case that narrowed the subtelomeric 19p13.3 microdeletion region to just 46 kilobases in a patient with cardiac, skeletal, speech, and motor traits.

The accumulated case reports on 19p13.3 deletions now paint a picture of remarkable phenotypic diversity. Published accounts include children with ocular manifestations, ptosis leading to the diagnosis of MAP2K2-linked cardiofaciocutaneous syndrome, lambdoid synostosis in combination with an inherited 16p13.11 microduplication, polyotia, high myopia, learning difficulties, and, in the mirror-image condition of 19p13.3 microduplication, nephrotic syndrome. Recent reports have expanded the spectrum further, describing feeding dysfunction and neurodevelopmental involvement in MAP2K2-related cardiofaciocutaneous syndrome type 4, and retinal development roles for genes such as RAX2. Against this backdrop, the new Iranian case, with its severe cardiomegaly and gastrointestinal manifestations, extends the known boundaries of the syndrome once again and reinforces the principle that deletion size and gene content are the primary determinants of clinical severity.

The research team, led by clinicians at Ali Asghar Children’s Hospital and Iran University of Medical Sciences in Tehran, obtained written informed consent from the parents and received ethics approval from their institution’s ethics committee. The authors declare no competing interests and no external funding for the work. While a single case cannot resolve which of the 55 deleted genes drives which symptom, reports of this kind serve as the raw material for that long-term effort, allowing researchers worldwide to align clinical features with genomic coordinates. For families affected by rare chromosomal disorders, and for the physicians who care for them, each carefully documented case shortens the diagnostic odyssey for the next child and brings the field a step closer to understanding how the loss of a tiny fragment of chromosome 19 can ripple through the development of the heart, the brain, the limbs, and the gut.

Subject of Research: 19p13.3 microdeletion syndrome and its clinical phenotype in a fatal infant case

Article Title: Phenotypic spectrum of 19p13.3 microdeletion: a fatal infant case with severe cardiomegaly and gastrointestinal manifestations

Article References: Eshghi, A., fargi, M. A., Pandi, M., & Tasharrofi, B. (2026). Phenotypic spectrum of 19p13.3 microdeletion: a fatal infant case with severe cardiomegaly and gastrointestinal manifestations. Molecular Biology Reports, 53(1), Article 1633. https://doi.org/10.1007/s11033-026-12791-x

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12791-x

Keywords: 19p13.3 microdeletion, chromosome 19, cardiomegaly, congenital heart defects, gastrointestinal manifestations, oligo-array CGH, MAP2K2, rare genetic disorder, developmental delay, recurrent pulmonary infections, copy-number variant, clinical genetics

Lymphatic vessels are best known as the body’s drainage network, collecting interstitial fluid, ferrying immune cells, and absorbing dietary fats. In most textbook accounts, they are supporting infrastructure rather than active participants in organ construction. The new study, published in the journal Genes & Development, challenges that view. Led by senior author Guillermo Oliver, the Thomas D. Spies Professor of Lymphatic Metabolism at Northwestern, the research demonstrates that cardiac lymphatic vessels send molecular signals to multiple types of heart cells, actively shaping how the growing heart regulates its own size.

The work builds directly on an earlier discovery from the Oliver laboratory, which showed that lymphatic vessels in the heart secrete a protein called Reelin. Reelin is famous in neuroscience, where it orchestrates the layered migration of neurons in the developing brain, but its role in the heart was a surprise. In that earlier work, the team found that Reelin promotes cardiac growth by stimulating the proliferation of cardiomyocytes, the contractile muscle cells that make up the bulk of the heart. When cardiomyocytes divide during embryonic development, the heart enlarges; when they stop dividing, as happens shortly after birth in mammals, that growth largely ceases.

The new study reveals that Reelin’s influence extends well beyond heart muscle. Using single-cell RNA sequencing, a technique that profiles gene expression in thousands of individual cells at once, combined with genetically engineered mouse models in which lymphatic-derived Reelin was eliminated, the researchers mapped a signaling pathway that connects the cardiac lymphatics to the epicardium, the thin layer of tissue that envelops the heart’s outer surface. The epicardium is far more than a protective membrane. During development it serves as a source of fibroblasts, coronary vascular cells, and growth factors, making it essential for normal cardiac morphogenesis.

What the team observed in mice lacking lymphatic-derived Reelin was striking. These hearts developed significant defects in the epicardium and lost specific populations of fibroblasts, the cells that build and maintain the heart’s structural scaffold. The investigators also documented a reduction in the number of epicardial cells expressing two critical cardiac factors: WT1, a transcription factor with well-established roles in epicardial biology and cardiac progenitor function, and insulin-like growth factor-1, or IGF-1, a potent growth factor that drives tissue expansion. In other words, removing a single lymphatic signal disrupted an entire regulatory network governing cardiac growth.

“We recently identified the cardiac lymphatic vasculature as an unexpected regulator of heart size during embryonic development,” Oliver said. “Here, by combining single-cell RNA sequencing with loss-of-function mouse models, we uncover another novel and unexpected critical regulatory network also participating in this process.” According to Oliver, the findings show that Reelin is not merely a muscle-cell proliferation signal but is essential for the maintenance and expansion of other cardiac cell types, including the epicardium and fibroblasts, and for sustaining the expression of WT1 and IGF-1, which together are responsible for the growth of the heart.

To test whether the mechanism holds in human tissue, the researchers turned to laboratory-grown human epicardioids, three-dimensional organoids that recapitulate key features of the developing heart’s outer lining. These mini-hearts, cultivated from human cells, allowed the team to probe Reelin’s effects in a controlled system that is more representative of human biology than mouse tissue alone. When the organoids were treated with Reelin protein, the expression of multiple epicardial markers increased, indicating that the protein promoted epicardial cell fate. This result supports the idea that Reelin directly influences epicardial maintenance during development and can even induce epicardial characteristics in the adult heart.

That last point carries significant implications for regenerative medicine. The mammalian heart loses most of its regenerative ability shortly after birth, and the epicardium, so active during embryogenesis, becomes largely dormant in the adult. Yet this dormant layer retains latent developmental programs that can be partially reawakened after injury, such as a heart attack, when the epicardium thickens and re-expresses genes like WT1. The Northwestern findings suggest that the beneficial effects of lymphatic vessels during adult cardiac injury may be partly mediated by Reelin reactivating the dormant epicardium, potentially leading to more efficient repair. If researchers could one day harness or mimic that signal, they might enhance the heart’s limited self-repair capacity after a myocardial infarction, the leading cause of death worldwide.

Timing appears to be everything. Oliver noted that Reelin expression in cardiac lymphatics declines progressively after birth and becomes nearly undetectable by day seven of life in mice. That postnatal decrease coincides precisely with the window in which newborn mice lose their ability to regenerate heart tissue, a phenomenon first described in landmark studies showing that a one-day-old mouse can fully repair its heart after surgical injury, while a seven-day-old mouse cannot. “This postnatal decrease coincides with the cessation of cardiac regeneration in newborn mice, suggesting that loss of Reelin may contribute to the arrest of these processes,” Oliver said. The correlation does not prove causation, but it provides a compelling lead for scientists trying to understand why the regenerative capacity of the heart switches off so early in life.

Beyond regeneration, the work may illuminate the origins of congenital heart defects, which affect roughly one percent of live births and often involve faults in the very cell types and signaling pathways the study identifies. If lymphatic-derived signals are required for proper epicardial maintenance, fibroblast development, and growth factor expression, then disruptions in cardiac lymphatic development could plausibly contribute to structural heart malformations, a hypothesis the authors suggest is worth investigating in future work.

Oliver and his colleagues have also proposed a broader and provocative conceptual model: that lymphatic vessels may function as organ-wide monitoring systems that help determine when growth is complete. As lymphatics grow into a developing organ, they are uniquely positioned to sample functional features of the tissue around them, including interstitial fluid pressure, the accumulation of metabolic waste, and tissue stiffness, all of which change as an organ matures. “What we propose is that it’s possible that lymphatics function as organ-level quality control systems,” Oliver said. In this view, the vessels continuously assess the organ’s condition and relay instructions: keep growing, keep proliferating, until the tissue reaches an appropriate state, and then stop.

If that model proves correct across organ systems, it would reframe the lymphatic vasculature from a passive drainage network into an active, instructive component of organogenesis, with Reelin as one of its molecular messengers. It would also connect two fields that have historically developed in parallel, lymphatic biology and cardiac developmental biology, around a shared question of size control. The technical achievements underpinning the study, from single-cell transcriptomics that resolved the cross-talk between lymphatic endothelial cells, epicardial cells, and fibroblasts, to the generation of human epicardioids that allowed direct functional testing, illustrate how modern tools are enabling biologists to dissect these multicellular conversations with unprecedented precision.

Much remains to be determined. The study was conducted in mice and in lab-grown organoids, and translating the findings to human therapy will require years of additional research, including work to establish whether Reelin signaling can be safely and effectively modulated in the injured adult heart. Still, the central message is clear and conceptually striking: the heart’s blueprint for growth is not written in muscle cells alone. It is co-authored by the lymphatic vessels threading through the organ, which whisper instructions to the epicardium, sustain the fibroblasts that build its framework, and keep the growth factors flowing until the job is done. Understanding that conversation, the Northwestern team argues, could ultimately give science new insight into how the heart responds to and repairs itself after a heart attack, turning a developmental curiosity into a potential therapeutic frontier.

Subject of Research: The role of lymphatic-derived Reelin signaling in regulating epicardial maintenance and cardiac growth during heart development

Article Title: Study reveals a new way the developing heart controls its growth

Article References: Study reveals a new way the developing heart controls its growth. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: cardiac lymphatics, Reelin, epicardium, heart development, cardiomyocyte proliferation, fibroblasts, WT1, IGF-1, organoids, regeneration, congenital heart defects, single-cell RNA sequencing

Single-ventricle physiology represents one of the most daunting challenges in pediatric cardiology. In these infants, effectively only one of the heart’s two pumping chambers functions properly, meaning a single ventricle must shoulder the work of supplying both the lungs and the rest of the body. These babies traditionally face growth failure, repeated hospitalizations, and substantial morbidity across the staged surgical palliation that keeps them alive. Against that backdrop, the demonstration by Blanco’s team that exclusive human milk feeding did not compromise growth velocity at three and six months is genuinely significant. Growth failure has long been considered almost inevitable in this population, and nutritional strategies are fiercely debated. The letter’s authors open by commending the trialists precisely because showing comparable growth with or without exclusive mother’s milk feeding challenges the assumption that human milk diets, which are calorically and compositionally different from formula, inevitably slow weight gain in cardiac infants.

Yet the correspondents push the interpretation further. They contend that judging human milk solely by anthropometric outcomes—weight, length, and head circumference—misses the deeper biological story. Human milk is not merely a delivery vehicle for calories and protein; it is a bioactive fluid containing hormones, growth factors, stem cells, oligosaccharides, and long-chain polyunsaturated fatty acids that participate directly in organ programming. The cardiovascular system, they argue, is among the organs most plausibly influenced by early nutrition, and the evidence for this influence now spans from the cellular level to decades of human life. Their letter assembles that evidence into a narrative they believe the field has underweighted when designing and interpreting feeding trials in critically ill neonates.

The conceptual backbone of their argument draws on the developmental origins of health and disease framework, crystallized in the influential hypothesis articulated by Atul Singhal and Alan Lucas in The Lancet more than two decades ago. That hypothesis proposed that early nutritional exposures leave lasting imprints on cardiovascular risk, with faster early growth in infancy paradoxically associated with later adverse cardiovascular profiles. In this view, the slower, more regulated growth supported by human milk is not a deficiency to be corrected but a programmed trajectory that favors long-term vascular and metabolic health. Applied to infants with congenital heart disease, the implication is striking: the population most vulnerable to cardiovascular complications across life may be precisely the population in which early milk feeding could exert its most meaningful protective programming.

Empirical support for that idea comes from several longitudinal studies the letter cites. Andrew Lewandowski and colleagues at the University of Oxford reported in Pediatrics that preterm infants who consumed more breast milk showed measurable differences in cardiac shape and function in young adulthood, with hearts that more closely resembled those of healthy term-born controls. In a remarkable piece of long-term epidemiology, Richard Martin and colleagues traced members of the Boyd Orr cohort to age sixty-five and found that individuals who had been breastfed as infants showed differences in carotid intima-media thickness and atherosclerotic plaque, structural markers of cardiovascular aging. More recently, Afif El-Khuffash and colleagues demonstrated in JAMA Network Open that among preterm infants, greater maternal breast milk intake in the first weeks of life was associated with better cardiac performance measures throughout the first year. And a 2025 study by Zhenjian Wang and colleagues in the European Journal of Clinical Nutrition extended the timeline again, associating breastfeeding duration with cardiac structure and function measured at four years of age.

None of these studies focused specifically on infants with single-ventricle physiology, and the letter’s authors are careful to frame them as convergent rather than conclusive. But the cardiac population is not without its own human-milk evidence. A 2022 systematic review by Kayla Elgersma and colleagues in Breastfeeding Medicine examined outcomes for infants with congenital heart disease and found associations between human milk feeding and improved clinical outcomes. A follow-up analysis published in 2023 in the Journal of the American Heart Association used propensity score matching within the National Pediatric Cardiology Quality Improvement Collaborative registry to show that human milk feeding and direct breastfeeding were linked to better outcomes for infants with single-ventricle congenital heart disease specifically. Propensity matching matters here, because it attempts to separate the effect of milk itself from the confounding influence of families who are, on average, more resourced and more engaged with care.

The letter also widens the lens beyond the heart to the lungs, an organ system inseparable from cardiovascular performance in neonates with compromised circulation. Verd and colleagues reference their own prior work arguing that human milk feeding deserves greater emphasis in preventing neonatal respiratory morbidity, alongside a systematic review and meta-analysis by Enrique Villamor-Martínez and colleagues showing that donor human milk protects against bronchopulmonary dysplasia, the chronic lung disease of prematurity. A 2022 study by Elena Moliner-Calderón and colleagues suggested that human milk feeding in septic newborns might reduce their exposure to ventilation therapy. For a baby with a single functioning ventricle, pulmonary vascular health is not a side issue; the entire palliation strategy depends on balanced pulmonary blood flow, and any intervention that reduces ventilator days or lung injury carries direct hemodynamic consequences.

What emerges from the correspondence is a methodological critique as much as a scientific one. The letter implicitly asks whether trials of exclusive human milk diets in cardiac neonates are being powered and designed around the wrong endpoints. Growth velocity is easy to measure and clinically important, but if the true benefits of human milk operate through cardiovascular programming, immune modulation, and pulmonary protection, then six-month growth curves may systematically underestimate the intervention’s value. The correspondents point to the Cochrane review by Fabrizio and colleagues on individualized versus standard fortification of human milk for preterm infants as evidence of how much methodological uncertainty still surrounds even basic questions of how to optimize milk-based feeding, let alone how to capture its long-term effects. Fortification itself—adding human milk-derived or bovine-based supplements to meet the elevated protein and mineral demands of fragile infants—remains an area where individualized approaches have not clearly outperformed standard protocols.

The clinical stakes are considerable. Infants with single-ventricle physiology undergo staged palliation beginning in the first days of life, and their nutritional status at each surgical stage influences operative risk, neurodevelopment, and survival. If human milk confers even modest cardiovascular and pulmonary advantages in this group, feeding protocols in cardiac intensive care units would need to change, and lactation support for mothers of critically ill newborns would become a therapeutic intervention rather than a wellness amenity. The letter’s authors, who span primary care pediatrics, research, and children’s heart units, are positioned to see both the bedside reality and the population-level evidence, and their argument is that the two have drifted apart: bedside practice often treats milk feeding as optional in cardiac infants, while the accumulating literature suggests it may be among the few modifiable factors with plausible lifelong impact.

Verd, Serra, and Costa-Orvay close their correspondence having made a focused case rather than a sweeping claim. They do not assert that mother’s milk reshapes the single ventricle, nor do they dispute the growth findings of the trial they address. What they do is redirect attention: growth equivalence is a floor, not a ceiling, for what human milk may achieve in critically ill neonates. The evidence they marshal—from sixty-five-year cohort follow-ups to propensity-matched cardiac registries—points toward early nutrition as a formative influence on the cardiovascular system, with the sickest newborns standing to gain the most. As randomized evidence in this population accumulates, the letter argues, trial designers should look beyond the growth chart and toward the heart itself, because that is where the milk may be doing its most important work.

Subject of Research: Effects of human milk feeding on cardiovascular development in critically ill neonates with congenital heart disease

Article Title: Cardiovascular development of critically ill neonates on mother’s milk

Article References: Verd, S., Serra, A., & Costa-Orvay, J. A. (2026). Cardiovascular development of critically ill neonates on mother’s milk. Pediatric Research. https://doi.org/10.1038/s41390-026-05510-6

Image Credits: AI Generated

DOI: 10.1038/s41390-026-05510-6

Keywords: human milk, single-ventricle physiology, congenital heart disease, neonatal nutrition, cardiovascular development, breastfeeding, pediatric cardiology, growth outcomes, bronchopulmonary dysplasia, developmental origins, preterm infants, Pediatric Research

The research team, led by pediatric cardiologist Margarita Zapata-Sánchez of Clínica Cardio VID in Medellín, Colombia, together with colleagues from the Fundación Cardiovascular de Colombia, examined twenty years of surgical experience across two specialized cardiovascular centers. They assembled a consecutive cohort of fifty-one children who underwent repair of an anomalous coronary artery origin, then divided the patients into three groups according to how the disease announced itself: those who were asymptomatic and discovered incidentally, those who arrived in acute heart failure, and those living with compensated chronic heart failure. The question was simple but clinically important. Does a heart that has been pushed into overt failure before surgery recover as well as one that was caught before symptoms appeared?

To answer it, the investigators tracked the left ventricular ejection fraction, or LVEF, the standard measure of how forcefully the heart’s main pumping chamber squeezes blood out with each beat. A healthy ventricle ejects more than half of the blood it contains with every contraction. In children with ALCAPA, chronic oxygen deprivation, or myocardial ischemia, can drive that number down dramatically, producing ventricular dysfunction, mitral valve leakage, and heart failure. The study’s primary outcome was the change in LVEF between the preoperative assessment and hospital discharge, a window that captures the earliest and most demanding phase of recovery, when the heart must adapt immediately after being reconnected to a proper arterial blood supply.

The distribution of clinical presentations tells its own story about how this defect behaves. Just over a quarter of the children, twenty-seven percent, were asymptomatic at diagnosis, meaning their anomaly was found without warning signs. More than half, fifty-one percent, presented with acute heart failure, often the dramatic first manifestation of the disease in infancy. The remaining twenty-two percent had chronic, compensated heart failure, a slower-burning form in which the heart and body have partially adapted to the chronic ischemia. Anomalous left coronary artery from the pulmonary artery accounted for ninety-two percent of all cases in the cohort, confirming that this variant dominates the spectrum of anomalous coronary origins from the pulmonary circulation in children.

Not surprisingly, the children who presented with heart failure arrived at the operating table in worse shape. The study documented more advanced preoperative disease and greater requirements for medical and mechanical support in these patients compared with their asymptomatic counterparts. Their ventricles were weaker, their physiology more fragile, and their perioperative course more demanding. This gradient of severity is exactly what the pathophysiology predicts: the longer the heart muscle is deprived of adequate coronary perfusion, the more extensive the injury, and the harder the recovery. What remained uncertain before this study was whether that preoperative damage would leave a lasting imprint on postoperative ventricular performance.

The surgical repair itself, in most cases, involved coronary reimplantation, which was used in nearly sixty-nine percent of patients. The technique involves detaching the anomalous coronary artery from the pulmonary artery and reattaching it directly to the aorta, restoring the normal dual-coronary anatomy and re-establishing high-pressure, oxygen-rich perfusion to the heart muscle. This is the operation that effectively reverses the fundamental defect: instead of stealing blood from the heart through the low-pressure pulmonary vessel, the coronary artery once again receives blood pushed into it by the aorta during diastole, the relaxation phase of the cardiac cycle when coronary filling normally occurs.

The results were unambiguous on the central question. Left ventricular ejection fraction improved significantly after surgery across the entire cohort, and by the time of hospital discharge it had normalized in all three presentation groups. When the researchers compared postoperative LVEF among the asymptomatic, acute heart failure, and chronic heart failure groups, they found no statistically significant differences, with a p-value of 0.918, essentially indicating that the groups were indistinguishable on this measure. Overall, recovery of ventricular function, defined as an ejection fraction above fifty percent, was achieved in eighty-six percent of patients. In other words, a heart that had been failing before surgery was, in most cases, pumping normally again within weeks of the operation, just like the hearts of children whose defects had been caught early.

But the study also delivered a sobering counterpoint. Although ventricular recovery was similar across groups, the children who had presented with heart failure paid a price in the immediate postoperative period. They experienced greater morbidity, meaning more complications and a more difficult convalescence, and they required longer hospitalizations. The heart muscle may forgive, but the body remembers the assault of preoperative failure. This finding reframes the clinical calculus: surgery restores pumping function with impressive consistency, yet the route a child takes to the operating room determines how rocky the road afterward will be. Early diagnosis does not change the destination of ventricular recovery, but it dramatically shortens and smooths the journey.

That message carries real weight for pediatric practice, particularly in regions where access to specialized cardiac care can be uneven. ALCAPA is rare, and its symptoms in infants, including poor feeding, sweating, irritability, and respiratory distress, can mimic far more common childhood illnesses, which delays diagnosis. The Latin American data underscore that every week of undetected ischemia increases the likelihood that a child will present in acute heart failure, with all the associated perioperative risks. The study’s authors argue that their findings highlight the importance of early diagnosis and timely surgical intervention, and the numbers bear that out: the asymptomatic group enjoyed the same excellent ventricular recovery as everyone else, but without the burden of extended hospital stays and postoperative complications.

The study also demonstrates the value of regional, multicenter collaboration in studying rare diseases. No single center sees enough cases of anomalous coronary artery origin to draw firm conclusions, but by pooling two decades of consecutive patients from two Latin American referral centers, the investigators produced a cohort large enough to compare outcomes across clinical presentations with genuine statistical power. The work was conducted under ethical approval from the Fundación Cardiovascular de Colombia and received no external funding. For the children of the region, and for clinicians everywhere who face this elusive diagnosis, the study provides reassurance that the pediatric heart possesses a striking capacity for recovery once its blood supply is restored, and a clear argument for finding the defect before it finds the child.

Subject of Research: Recovery of left ventricular function in children after surgical repair of anomalous coronary artery origin from the pulmonary artery

Article Title: Recovery of left ventricular function in children following repair of anomalous coronary artery origin according to clinical presentation: a multicenter study from Latin America

Article References: Recovery of left ventricular function in children following repair of anomalous coronary artery origin according to clinical presentation: a multicenter study from Latin America. (n.d.). https://doi.org/10.1186/s12887-026-07713-6

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07713-6

Keywords: anomalous coronary artery origin, ALCAPA, left ventricular ejection fraction, pediatric cardiac surgery, congenital heart defects, heart failure, myocardial ischemia, coronary reimplantation, ventricular recovery, Latin America, BMC Pediatrics, early diagnosis

Down syndrome, caused in about 95 percent of cases by a full extra copy of chromosome 21, is the most common chromosomal disorder associated with intellectual disability. Its effects ripple across the neurological, musculoskeletal, and cardiovascular systems, and roughly half of all individuals with the condition are born with congenital heart defects. Over the past decade, researchers have documented widespread epigenetic alterations, changes to chemical marks on DNA that regulate gene activity without altering the underlying sequence, in the nuclear DNA of people with trisomy 21. These changes have been linked to features ranging from accelerated aging to hematological and cardiovascular complications. But the mitochondrial genome has remained largely terra incognita for epigeneticists, even as evidence accumulates that mitochondrial dysfunction is a genuine feature of the syndrome.

The reason mitochondria matter so much in Down syndrome comes down to gene dosage. The extra chromosome carries genes involved in oxidative stress pathways, and cells from people with the syndrome show impaired energy metabolism, chronic pro-oxidative states, and deficits in the molecular machinery that produces ATP, the cell’s energy currency. Studies in fibroblasts and brain tissue have repeatedly detected these functional disturbances. Yet measuring mitochondrial function directly is difficult, and one of the most accessible molecular proxies, the number of mitochondrial DNA copies per cell, has yielded only slight and statistically unconvincing increases in prior studies of Down syndrome tissues.

The new study focused on a very specific stretch of the mitochondrial genome: the D-loop, a non-coding regulatory region that contains both the origin of DNA replication and the main transcription start site for the mitochondrial chromosome. The D-loop is where DNA methyltransferases, the enzymes that attach methyl groups to cytosine bases, appear to concentrate their activity on mitochondrial DNA. Although methylation levels across the mitochondrial genome are typically very low, around 0.5 to 1 percent, the D-loop can reach peaks of 10 to 15 percent. Crucially, methylation in this region modulates the binding of TFAM, mitochondrial transcription factor A, a master regulator of both mitochondrial DNA transcription and replication. In diseases from Alzheimer’s to amyotrophic lateral sclerosis to cardiovascular conditions, D-loop methylation has been found altered and sometimes correlated with disease severity and mitochondrial DNA copy number, making it a plausible suspect in Down syndrome as well.

The suspicion was sharpened by a single earlier study from 2011, in which researchers examined immortalized lymphoblastoid cells from six children with Down syndrome and six matched controls. That work identified a breakdown in one-carbon metabolism, the cellular circuit that generates the methyl-donor molecule S-adenosylmethionine, and found reduced levels of this methylating agent inside the mitochondria of Down syndrome cells, along with global hypomethylation of mitochondrial DNA. If mitochondrial methylation capacity was genuinely compromised, it stood to reason that measurable differences should appear in patient blood samples.

To find out, the team led by Andrea Stoccoro and Fabio Coppedè of the University of Pisa, working with colleagues at the University of Rijeka and the Juraj Dobrila University of Pula, recruited 118 participants at the Clinical Hospital Centre Rijeka in collaboration with Down syndrome associations across Croatia. The cohort ranged in age from newborns to 55 years, with every Down syndrome case confirmed by karyotyping and every participant matched by age and sex to a healthy control. Among the newborns, ten had Down syndrome with congenital heart defects, eight had Down syndrome without such defects, and eighteen were healthy controls. The heart defects identified by ultrasound included five atrial septal defects, two atrioventricular septal defects, one ventricular septal defect, one patent ductus arteriosus, and one case of tetralogy of Fallot, and newborn blood samples were drawn within seventy-two hours of birth, before any surgical or medical correction of cardiac malformations could confound the measurements.

Methodologically, the study leaned on methylation-sensitive high-resolution melting, a technique that amplifies a bisulfite-converted segment of DNA and then reads out its methylation level from the melting behavior of the resulting PCR product. The team had previously developed and validated this protocol against pyrosequencing, and in the present study it targeted a 222-base-pair segment of the D-loop containing ten CpG sites. Calibration standards spanning 0 to 100 percent methylation were run in each assay, and an interpolation method developed in the same laboratory converted melting curves into precise single-value methylation percentages. Bisulfite conversion efficiency averaged 99 percent, and equal numbers of patient and control samples were processed together to suppress batch effects. Mitochondrial DNA copy number was measured independently by quantitative PCR comparing a mitochondrial target against the nuclear hemoglobin beta gene, with the caveat that limited DNA availability allowed copy number analysis in only 103 of the 118 participants.

The results were striking in their uniformity. Across individuals, D-loop methylation ranged from 0 to about 8 percent, and mitochondrial DNA copy number ranged from 33 to 900 copies, reflecting enormous person-to-person variability. But the distributions overlapped almost perfectly between groups. Median D-loop methylation was 1.3 percent in controls versus 4.0 percent in the Down syndrome group, a difference that fell short of statistical significance at p equal to 0.28. Mitochondrial DNA copy number medians were similarly indistinguishable, at roughly 128 copies in controls and 149 in the syndrome group, with p equal to 0.22. Age showed no correlation with either biomarker across the entire sample, spanning newborns to mid-adulthood. Sex made no significant difference either, although the authors noted a slight, non-significant tendency toward higher copy number in males. Most importantly for the congenital heart question, comparisons among the three newborn groups, those with Down syndrome and heart defects, those with Down syndrome and healthy hearts, and controls, revealed no differences in either methylation or copy number, with p values of 0.85 and 0.60 respectively.

The authors are careful to frame the work as a pilot study and to spell out its limits. The analysis covered only a small portion of the mitochondrial genome, so alterations elsewhere in the mitochondrial chromosome cannot be excluded. The newborn subgroup, particularly those without heart defects, was small, and too small to permit sex-stratified analysis even though previous genome-wide studies of nuclear DNA in Down syndrome newborns have shown that many methylation differences tied to congenital heart defects are sex-specific. Blood methylation may also simply fail to mirror what happens in fetal cardiac tissue, the site where the relevant biology would actually unfold. Larger cohorts and studies of cardiac tissue itself will be needed before mitochondrial methylation can be definitively ruled out in the syndrome’s cardiovascular complications.

Even so, the null result carries a useful message. It suggests that the mitochondrial dysfunction documented in Down syndrome, including the more pronounced oxidative stress seen in fetuses with congenital heart defects, does not register in the two most accessible mitochondrial molecular readouts available from a routine blood sample. Unlike nuclear DNA methylation, where robust signatures of trisomy 21 have been detected in blood, placenta, buccal cells, brain, and myocardial tissue, the mitochondrial D-loop appears to hold steady. For researchers hunting biomarkers that could distinguish Down syndrome newborns with heart defects from those without, the message is that the mitochondrial D-loop is unlikely to provide one, at least not in peripheral blood. For the broader field of mitochondrial epigenetics, the study adds a well-controlled data point to a growing literature showing that D-loop methylation shifts in some neurological and cardiovascular diseases but not in every condition marked by mitochondrial stress, a reminder that in biology, the absence of a signal can be as informative as its presence.

Subject of Research: Mitochondrial D-loop region methylation and mitochondrial DNA copy number in individuals with Down syndrome

Article Title: Analysis of mitochondrial D-loop region methylation and copy number in peripheral blood DNA of Down syndrome individuals including newborns with and without congenital heart defects

Article References: Analysis of mitochondrial D-loop region methylation and copy number in peripheral blood DNA of Down syndrome individuals including newborns with and without congenital heart defects. (n.d.). https://doi.org/10.1186/s43682-025-00039-x

Image Credits: AI Generated

DOI: 10.1186/s43682-025-00039-x

Keywords: Down syndrome, mitochondrial DNA, D-loop methylation, mtDNA copy number, epigenetics, congenital heart defects, trisomy 21, bisulfite conversion, high-resolution melting, mitochondrial dysfunction, newborns, biomarkers

The research team, led by Huang and colleagues, set out to answer questions that have persisted in the clinical literature for years. Although the association between Turner syndrome and congenital heart disease is well established, with left-sided obstructive lesions such as bicuspid aortic valve, coarctation of the aorta, and partial anomalous pulmonary venous connection appearing at rates far above those seen in the general population, the baseline metabolic profile of these patients and the trajectory of their recovery after cardiac surgery have remained poorly characterized. Most prior studies have either focused on the cardiac phenotype in isolation or examined metabolic complications in adult cohorts without accounting for the presence of structural heart disease. By bringing these two domains together in a single analysis, the investigators hoped to illuminate the mechanisms through which chromosomal, cardiovascular, and metabolic pathology converge.

The clinical significance of this convergence is difficult to overstate. Turner syndrome results from the complete or partial absence of one X chromosome in phenotypic females, and the consequences ripple across nearly every organ system. Patients typically exhibit short stature due to haploinsufficiency of the SHOX gene, primary ovarian failure requiring hormone replacement therapy, renal anomalies, lymphedema, and distinctive skeletal features. But it is the cardiovascular system where the syndrome exacts its heaviest toll. Congenital heart disease affects an estimated 30 to 50 percent of individuals with Turner syndrome, and even in the absence of structural defects, patients face accelerated aortic root dilation, heightened risk of aortic dissection, and premature coronary artery disease. Meanwhile, metabolic disturbances — insulin resistance, type 2 diabetes, dyslipidemia, nonalcoholic fatty liver disease, and hypertension — are documented at rates several-fold higher than in age-matched peers.

Against this backdrop, the new study examined a cohort of Turner syndrome patients with congenital heart disease who had undergone surgical correction, characterizing their metabolic features before operation and tracking early postoperative outcomes. The researchers compiled anthropometric measurements, lipid panels, glycemic indices, and markers of insulin resistance alongside detailed cardiac anatomical diagnoses and perioperative data. This design allowed the team to ask whether the metabolic phenotype of Turner patients with structural heart disease differs meaningfully from what has been reported in Turner patients without heart defects, and whether metabolic status influences how patients fare in the critical days and weeks following cardiac surgery.

One of the study’s central observations concerns the interplay between body composition and metabolic risk. Turner syndrome patients are known to have a distinctive body composition profile, characterized by increased visceral adiposity relative to total body mass, elevated waist-to-hip ratios, and a tendency toward central fat accumulation even in individuals of normal weight. This “thin on the outside, fat on the inside” phenotype predisposes patients to insulin resistance that is often underestimated by standard body mass index screening. The new findings reinforce the concern that children and adolescents with Turner syndrome and congenital heart disease may already manifest early metabolic abnormalities — elevated triglycerides, reduced high-density lipoprotein cholesterol, impaired glucose tolerance — at ages when preventive intervention could still alter their lifetime trajectory.

The growth hormone therapy widely used to treat short stature in Turner syndrome adds another layer of metabolic complexity. Growth hormone is a counter-regulatory hormone that antagonizes insulin action, and while treatment at standard doses is generally considered metabolically safe, the combination of growth hormone exposure, estrogen replacement, and underlying congenital heart disease creates a metabolic milieu that clinicians must navigate carefully. The study’s baseline characterization provides a reference point against which the metabolic effects of these therapies can be judged in patients undergoing cardiac surgery, a population in whom hormonal regimens are often adjusted perioperatively with limited evidence to guide decision-making.

Beyond the metabolic portrait, the study’s analysis of early postoperative outcomes carries immediate practical implications for surgical and intensive care teams. Cardiac surgery triggers a well-described metabolic stress response: cortisol and catecholamine levels surge, insulin resistance deepens, and hyperglycemia frequently develops even in patients with no prior glycemic abnormality. In patients who begin surgery already insulin resistant, this stress response can be amplified, and postoperative hyperglycemia has been linked in numerous studies to increased rates of wound infection, arrhythmia, prolonged mechanical ventilation, and longer intensive care unit stays. The findings in Turner syndrome patients with congenital heart disease suggest that clinicians should view these patients as a metabolically vulnerable group in whom perioperative glycemic management, nutritional support, and monitoring for metabolic complications deserve heightened attention.

The connection between congenital heart disease itself and metabolic derangement adds further intrigue. Children born with structural heart defects, particularly obstructive left-sided lesions, often experience chronic low cardiac output, reduced exercise tolerance, and altered growth patterns that can shape metabolic development long before surgical correction. Coarctation of the aorta, one of the signature lesions of Turner syndrome, produces chronic upper-body hypertension that may predispose to endothelial dysfunction and accelerated vascular aging. When this vascular burden is superimposed on the chromosomal predisposition to insulin resistance and dyslipidemia, the resulting cardiometabolic risk profile may exceed the simple sum of its parts. The study’s integrated characterization of anatomy and metabolism within the same cohort provides a rare opportunity to begin disentangling these contributions.

The implications extend into the adult transition period, which has long been identified as a danger zone for Turner syndrome care. Girls with the condition are typically managed intensively in childhood through multidisciplinary clinics that coordinate growth hormone therapy, cardiology surveillance, and endocrine monitoring. But as patients reach adolescence and young adulthood, follow-up often fragments, and metabolic screening — like cardiac imaging — is frequently performed less diligently than guidelines recommend. Adult cardiologists may focus on aortic surveillance while overlooking lipid panels and glucose tolerance, while endocrinologists may manage hormone replacement without adequate attention to the cardiovascular context. The new evidence that metabolic features correlate with postoperative outcomes offers a concrete clinical rationale for keeping metabolism at the center of care across the lifespan, rather than treating it as a secondary concern.

It is worth emphasizing what the study does and does not establish. The findings characterize associations within a surgical cohort and cannot, by themselves, prove that metabolic abnormalities cause adverse postoperative outcomes or that correcting metabolic disturbances before surgery would improve recovery. Causal inference in this domain would require longitudinal designs, ideally beginning in infancy and following patients through surgical intervention and beyond, with careful adjustment for confounders such as age at surgery, lesion type, surgical technique, and hormonal treatment history. The authors’ work nonetheless establishes an evidentiary foundation for such studies and provides clinically actionable descriptive data in a population that has historically been underrepresented in cardiac surgical research.

The broader scientific context makes the study timely. Over the past decade, researchers have increasingly recognized that congenital heart disease is not a condition that ends at surgical correction but a lifelong cardiovascular syndrome with metabolic, neurodevelopmental, and vascular dimensions. Simultaneously, Turner syndrome specialists have pushed for earlier and more aggressive cardiometabolic screening, citing evidence that women with the condition die from cardiovascular causes at rates far exceeding background risk and at strikingly young ages. The convergence of these two research currents — one centered on the long-term consequences of congenital heart surgery, the other on the systemic manifestations of sex chromosome aneuploidy — makes the present study a natural and important synthesis.

For families of girls with Turner syndrome and congenital heart disease, the message emerging from this research is one of vigilance rather than alarm. The study underscores that routine metabolic evaluation — lipid profiles, fasting glucose or hemoglobin A1c, and assessment of body composition — should be considered a standard component of cardiac care in this population, both before and after surgery. For clinicians, the findings argue for perioperative protocols that anticipate metabolic stress and monitor glycemic control with particular care in Turner patients. And for researchers, the work opens a path toward interventional trials testing whether early metabolic optimization can translate into better surgical outcomes and longer, healthier lives for a group of patients who have waited far too long for evidence built around their unique biology.

p class=”c-bibliographic-information__citation”>Huang, Y., Luo, S., Qi, Y. et al. Metabolic features and postoperative outcomes in Turner syndrome with congenital heart disease. Pediatric Research (2026). https://doi.org/10.1038/s41390-026-05450-1

Hearts, among the earliest organs to develop in vertebrates, perform the essential function of circulating oxygen and nutrients necessary for embryonic growth. Yet, the precise biological mechanisms orchestrating the transformation of the heart’s muscular architecture, specifically the formation of trabeculae, have remained elusive. Trabeculae are intricate muscular ridges found inside the ventricles, known to be critical for efficient blood flow and mechanical function. By exploiting the genetic and structural homologies between zebrafish and human hearts, combined with the transparency of zebrafish embryos, the researchers were able to observe trabecular development with unprecedented spatial and temporal resolution.

Contrary to long-held assumptions that trabecular muscle expands through the proliferation of existing cells, this study reveals that trabecular growth primarily occurs by recruiting adjacent cardiomyocytes rather than by cell division. This discovery alters our fundamental understanding of heart muscle formation, indicating a sophisticated intercellular communication system that governs the addition of cells to the trabeculae network. The recruitment process enhances the heart’s muscular mass and contractile efficiency in a highly coordinated manner, optimizing cardiac output as the organ matures.

Perhaps the most groundbreaking revelation from this investigation is the discovery of a mechanochemical feedback loop that intimately links cardiac contractions to the structural remodeling of the heart itself. As trabeculae develop and heartbeats intensify, these mechanical forces generate biological signals that alter the physical properties of cardiomyocytes. The cells become mechanically ‘softer,’ allowing them to elongate and increase in volume. This cellular softening is critical, as it enables the heart chamber to expand its volume by nearly ninety percent, significantly increasing its capacity to fill with blood during diastole.

This feedback mechanism also acts as a regulatory brake on trabecular expansion. As cardiomyocytes stretch and enlarge, they concurrently lose their ability to be recruited into the trabecular network, effectively stabilizing tissue growth and preventing excessive or disorganized cardiac muscle proliferation. This dynamic equilibrium ensures that the heart develops to an optimal size and functional capability that matches physiological demands without compromising structural integrity.

Toby Andrews, the study’s first author and a postdoctoral fellow at the Crick Institute, emphasized the significance of these findings: “The heartbeat, synonymous with life, has been observed for centuries, yet the orchestration of its growth remains a biological enigma. What we are discovering is that the heart is not simply pre-programmed but rather exhibits intelligent adaptability to physiological needs. Such plasticity is vital, especially for understanding how deviations in heart development may underlie disease.”

These insights open new avenues for exploring therapies that could harness or mimic these natural mechanosensitive growth processes to repair damaged hearts. By understanding how the heart tunes its own development through the interplay of mechanical forces and cellular responses, scientists may design interventions that promote healthy regeneration or prevent maladaptive remodeling post-injury.

The research team intends to further dissect the complexities of trabecular architecture, particularly as these muscular ridges evolve into an intricate sponge-like meshwork within the heart ventricles. Future investigations will focus on elucidating how trabecular patterns influence blood flow dynamics and contribute to the biomechanical environment within the heart. Understanding the molecular signaling pathways driving this intricate morphogenesis will be critical for comprehending cardiomyopathies and other malformations linked to trabecular defects.

Rashmi Priya, head of the Organ Morphodynamics Lab at the Crick, underscored the clinical relevance of this research: “Although we have made strides in identifying molecular pathways linked to cardiomyopathies, the formation and function of trabeculae remain poorly understood. This limits our capacity to tackle heart diseases rooted in developmental abnormalities. Decoding the mechanisms that mold these muscular structures will illuminate new biological principles guiding one of nature’s most efficient pumps.”

The study exemplifies the power of interdisciplinary and innovative technological approaches in life sciences. Utilizing live 4D microscopy coupled with biomechanical measurements allowed the researchers to interrogate developmental processes from the cellular to the organ level. This holistic view is crucial in capturing the emergent properties of biological tissues, particularly in organs like the heart where form and function are inextricably linked.

Funded by the British Heart Foundation, this research showcases the transformative potential of foundational biological discovery to impact human health. By unraveling how mechanical forces are transduced into biological signals that modulate cell behavior and tissue growth, this work not only enriches our fundamental understanding of developmental biology but also lays the groundwork for novel strategies in regenerative medicine.

The Francis Crick Institute, a leading biomedical research center, continues to make strides in unraveling the fundamental mechanisms of health and disease. Its collaborative environment brings together scientists from multiple disciplines, fostering groundbreaking discoveries that help translate molecular and cellular insights into therapeutic innovations. This study sets a new standard for how detailed mechanobiological research can uncover the hidden intelligence embedded within living tissues.

As the heart’s rhythmic contractions orchestrate its own growth, this research redefines the heart not merely as a passive pump but as an active architect of its form and function. The discovery that the beating heart directs its development through a sophisticated feedback system opens exciting horizons for cardiovascular biology and medicine.

Subject of Research: Heart development and growth mechanisms in zebrafish, focusing on trabecular morphogenesis and mechanochemical feedback between cardiac contraction and cellular remodeling.

Article Title: Mechanochemical coupling of cell shape and organ function optimizes heart size and contractile efficiency in zebrafish.

News Publication Date: 6 August 2025

References: Andrews et al. (2025), Developmental Cell

Keywords: Heart muscle, developmental stages, mechanochemical feedback, trabeculae, cardiac morphogenesis, zebrafish heart development, cardiomyocyte recruitment, cardiac remodeling, congenital heart defects, biomechanical signaling

Ion channels like PIEZO2 have long fascinated scientists due to their exquisite sensitivity to mechanical forces. Embedded in the membranes of various cell types, PIEZO2 channels convert physical stimuli, such as pressure or stretch, into biological signals. These channels underlie our ability to perceive gentle breezes and even the faintest touches on the skin. However, Dr. Hammes and her team have demonstrated that PIEZO2’s functional repertoire extends into the realm of cardiovascular morphology, particularly within the developing heart’s vascular system.

Utilizing advanced mouse models genetically engineered to lack or overexpress PIEZO2 in endothelial cells, the research team meticulously charted the consequences of altered PIEZO2 activity on coronary artery development. Their findings were striking: in the absence of PIEZO2, coronary vessels often failed to mature properly, resulting in abnormally narrow or misbranched arteries. This vascular malformation compromised oxygen delivery to the heart muscle, instigating compensatory hypertrophy – a thickening of cardiac tissue primarily observable in the left ventricle. Conversely, mice harboring a hyperactive PIEZO2 variant displayed parallel defects, illuminating the finely tuned balance required for normal cardiovascular patterning.

The clinical significance of these results is underscored by the connection between PIEZO2 mutations and rare human conditions, including Marden-Walker syndrome—a genetic disorder associated with aberrant PIEZO2 function. The team’s findings suggest that mechanotransduction via PIEZO2 is indispensable for orchestrating the biomechanical signals that guide coronary vessel morphogenesis, implicating faulty PIEZO2 activity in congenital cardiovascular abnormalities. Furthermore, genome-wide association studies in humans have linked PIEZO2 variants to prevalent cardiovascular diseases such as heart failure, hypertension, and aneurysm formation, reinforcing the broader impact of this mechanosensitive channel beyond embryonic development.

Technically, the researchers employed cutting-edge tissue clearing methods combined with light sheet microscopy to visualize coronary artery formation in unprecedented detail. By staining developing vessels with specific antibodies targeting PIEZO2-expressing endothelial cells, they captured high-resolution three-dimensional images demonstrating the spatial distribution and branching patterns of coronary arteries throughout embryonic stages. This approach facilitated an in-depth analysis of how altered ion channel signaling perturbs vascular architecture, bringing to light mechanisms that were previously invisible to conventional histological techniques.

A particularly intriguing aspect of PIEZO2 revealed by the study is its temporal expression pattern. The ion channel is predominantly active during embryogenesis within the endothelial cells of coronary arteries, orchestrating vascular formation before becoming largely silent after birth. However, emerging evidence suggests that PIEZO2 may be reactivated in adult hearts under pathological conditions, such as ischemic injury or coronary artery disease. This re-expression holds exciting therapeutic potential for promoting vascular regeneration and repair, positioning PIEZO2 as a candidate target for novel cardiovascular treatments.

Building on these preclinical insights, Dr. Hammes and colleagues are now extending their work to human models. Collaborations with the Helmholtz Institute for Translational AngioCardioScience and the Max Delbrück Center’s Pluripotent Stem Cell Technology Platform enable the use of human endothelial cells derived from pluripotent stem cells. This platform allows precise manipulation and observation of PIEZO2 expression and activity in human vascular cells, potentially bridging the translational gap between murine findings and clinical applications.

This translational approach is poised to catalyze breakthroughs in diagnostic precision. By enhancing our understanding of the genetic and molecular bases of congenital heart defects via PIEZO2 pathways, early identification of at-risk individuals could become feasible. Moreover, targeting PIEZO2 function pharmacologically could provide a preventative strategy against the progression or onset of cardiovascular diseases rooted in vascular developmental anomalies.

The research also prompts a reevaluation of the role of mechanosensation in cardiovascular biology. Traditionally associated with sensory neurons and touch perception, channels like PIEZO2 are now recognized as pivotal molecular transducers integrating mechanical forces during organogenesis. These forces guide cellular behavior, vascular remodeling, and tissue homeostasis in complex and dynamic ways, underscoring the interdisciplinary nature of modern cardiovascular research.

Crucially, the study spotlights the Max Delbrück Center’s unique collaborative environment, where multidisciplinary teams converge to tackle the intricacies of disease mechanisms. Contributions from labs specializing in molecular signaling, endothelial biology, and cardiac physiology collectively facilitated a comprehensive elucidation of PIEZO2’s role. This synergy exemplifies how integrating diverse expertise accelerates discovery and fosters innovation that can directly impact patient care.

Beyond the immediate cardiovascular implications, these findings may also influence related fields such as developmental biology, regenerative medicine, and genetic disease research. Understanding how mechanical forces are sensed at the molecular level to sculpt organ systems could inform strategies to engineer tissues or modulate cell behavior in various contexts, ultimately enhancing regenerative therapies.

In conclusion, the unveiling of PIEZO2 as a mechanosensitive ion channel essential to coronary artery development marks a paradigm shift in cardiovascular biology. This pioneering research by Dr. Hammes and her team not only deepens our comprehension of the molecular mechanisms governing heart formation but also opens new frontiers for diagnostic and therapeutic innovation aimed at combating congenital and acquired heart diseases. As investigations proceed into human models and adult cardiac pathology, PIEZO2 may emerge as a fate-shaping conduit between biomechanics and medicine.

Subject of Research: Animals

Article Title: Mechanosensitive PIEZO2 channels shape coronary artery development

News Publication Date: 27-Jun-2025

Web References:

• Hammes lab: https://www.mdc-berlin.de/hammes
• Lewin lab: https://www.mdc-berlin.de/lewin
• Gerhardt lab: https://www.mdc-berlin.de/gerhardt
• Hübner lab: https://www.mdc-berlin.de/huebner
• Helmholtz Institute for Translational AngioCardioScience: https://www.mdc-berlin.de/hi-tac
• Pluripotent Stem Cell Technology Platform: https://www.mdc-berlin.de/pluripotent-stem-cells

References:
DOI: http://dx.doi.org/10.1038/s44161-025-00677-3

Image Credits:
Mireia Pampols-Perez, Max Delbrück Center

Keywords:
PIEZO2, coronary artery development, mechanosensitive ion channels, congenital heart defects, endothelial cells, mechanotransduction, cardiac hypertrophy, vascular morphogenesis, Pluripotent Stem Cells, cardiovascular regeneration

This study holds the distinction of being the first comprehensive examination of congenital heart defect rates post-Dobbs decision. Academics and health professionals have noted that the incidence of CCHD remained stable in states that upheld abortion access, while alarming increases were recorded in those that restricted the procedure. The findings are significant, as the reported incidence in restrictive states surpasses prior model estimates that forecasted rates without the influence of the Dobbs ruling. This highlights a potential public health crisis that has emerged in the wake of shifting abortion policies.

CCHD comprises a variety of complex heart defects that limit oxygen delivery throughout the body, making immediate medical intervention critical for survival. Traditionally, a notable percentage of infants born with CCHD necessitate surgical efforts in their early neonatal period to ensure their chances at life. Even more striking is the statistic that approximately 15% to 20% of these infants face mortality within their first year of life. Those who survive often have lifelong medical needs revolving around cardiology care, which encompasses routine check-ups, diagnostic testing, and possibly more advanced therapeutic procedures or surgical interventions later in life.

Dr. Stephanie Tseng, an assistant professor and pediatric cardiologist at Nationwide Children’s Hospital, has articulated the profound implications of these findings on the health care landscape. She emphasizes that as the prevalence of CCHD births rises, the health care infrastructure—especially within states with limited abortion options—must adequately prepare for an influx of patients requiring extensive and ongoing care. This preparation encompasses not only financial resources and health care infrastructure but also the emotional and physical strains that may weigh heavily on affected families as they navigate the challenges of caring for children with complex medical needs.

Despite the compelling nature of these observations, Dr. Tseng cautions against definitively attributing causal relationships solely to changing abortion access laws. There are myriad factors that could potentially influence these disparities in CCHD birth rates. Variations in maternal health care practices, prenatal diagnostics, and regional differences in maternal risk factors such as diabetes could all contribute to the divergent data on congenital heart disease. The multifaceted nature of congenital heart defects calls for a nuanced understanding of the interplay between legislative policy and public health outcomes.

Prenatal diagnostics, particularly via ultrasound, typically facilitate the early identification of CCHD, commonly during the second trimester of pregnancy. However, the complexities of the condition can sometimes result in diagnoses that are only made after birth, complicating both parental expectations and medical responses. While the precise origins of CCHD often remain elusive, it is generally accepted that a combination of genetic predispositions and environmental influences may contribute to these life-altering defects.

The researchers involved in the study reviewed birth statistics sourced from the U.S. Centers for Disease Control and Prevention, focusing on data from newborns delivered between 2016 and 2024 in states characterized by restrictive abortion laws and contrasting those with states known for their protective abortion policies. By parsing through monthly birth data, the team noted a distinct divergence in CCHD rates immediately following the Dobbs ruling, with their observations revealing a startling median difference of approximately 9.6 cases per 100,000 births, illustrating a clear uptick in reported cases.

Another critical aspect of the research involved quantitatively assessing the difference in CCHD incidence over time against expected rates extrapolated from pre-Dobbs trends. The results indicated a notable divergence post-Dobbs, with most observed instances exceeding the forecasted incidence, underscoring the magnitude of the shifts occurring in states governed by stricter abortion laws. Researchers expressed a plausible hypothesis: families who may have chosen to terminate pregnancies upon a CCHD diagnosis may now be compelled to carry those pregnancies to term due to restrictive abortion policies.

Dr. Tseng poignantly remarked on the journey of care available for children with congenital heart defects, acknowledging the advancements made while recognizing the still-high mortality rates associated with severe forms of CCHD. Certain congenital defects can present dire prognoses with limited surgical options available, leading some families to consider termination based on the projected quality of life for both the child and the family. The shift in reproductive rights amid evolving legal landscapes poses ethical dilemmas alongside the implications for maternal health and child well-being.

Ultimately, the implications of this study extend beyond mere statistical observation. They call for an urgent reevaluation of health care resources and readiness in anticipation of a growing cohort of individuals affected by CCHD. As the landscape of reproductive rights continues to shift post-Dobbs, there is a pressing need for ongoing monitoring of these trends. By tracking these developments, health systems can better allocate resources and arm themselves to meet the increased needs of children who will require lifelong monitoring and care due to their congenital heart conditions.

Though the study’s limitations prevent definitive conclusions regarding specific CCHD diagnoses or the timing of their identification, the data presented is striking enough to warrant deeper investigation and sustained attention in both public health discussions and legislative considerations. As health care professionals and policymakers grapple with the ramifications of the changing legal framework surrounding reproductive rights, it becomes increasingly vital to prioritize the needs of the most vulnerable populations—newborns and their families affected by congenital heart defects.

In conclusion, the rising incidence of CCHD in states with restrictive abortion laws presents a multifaceted public health challenge. This situation necessitates rigorous research and funding to ensure that health care systems are equipped to provide adequate support for infants and families coping with complex congenital heart disease. The intersection of reproductive rights and health care is becoming increasingly complex, demanding sensitivity, ongoing dialogue, and proactive measures to safeguard the well-being of all families involved.

Subject of Research: Impact of Abortion Laws on Congenital Heart Disease Rates
Article Title: Rise in Births of Infants with Cyanotic Congenital Heart Disease Following Restrictive Abortion Laws
News Publication Date: March 30, 2025
Web References: CardioSmart.org/congenital-heart-disease
References: American College of Cardiology Annual Scientific Session (ACC.25)
Image Credits: American College of Cardiology

Keywords: Congenital heart disease, abortion laws, CCHD, public health, pregnancy termination, maternal care, health policy.